Biogen, Eisai sink as much-awaited Alzheimer’s results raise more questions
July 26, 2018 at 11:07 AM EDT
The drug, dubbed BAN2401, slowed declines associated with Alzheimer’s disease by 30 percent at its highest dose in the trial, compared with placebo, after 18 months.